Clinical trial
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or…
NCT00017069 · CTI BioPharma, Industry · Terminated
Key facts
| NCT number | NCT00017069 |
|---|---|
| Title | Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma |
| Official title | CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | CTI BioPharma, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | arsenic trioxide, dexamethasone |
| Start date | Feb 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 5, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: